FibroGen posts Q3 net income of $200.6 mln after sale of China operations
FibroGen reported a Q3 net income of $200.6 million, primarily due to the sale of its China operations to AstraZeneca for $220 million. Revenue from continuing operations rose to $1.1 million. The company anticipates its cash resources will support operations until 2028, with interim results from the FG-3246 trial expected in 2026. Analysts maintain a "buy" rating on FibroGen, with a median 12-month price target of $43.00, significantly above its recent closing price of $11.03.
)
Overview
- FibroGen Q3 net income $200.6 mln, driven by sale of China operations
- Revenue from continuing operations in Q3 was $1.1 mln, up from $0.1 mln in Q3 2024
- Company expects cash to fund operations into 2028
Outlook
- FibroGen expects cash resources to fund operations into 2028
- Interim results from FG-3246 trial expected in second half of 2026
- FibroGen to submit Phase 3 roxadustat protocol in 4Q 2025
Result Drivers
- CHINA OPERATIONS SALE - Sale of FibroGen China to AstraZeneca for $220 mln simplified capital structure and extended cash runway
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net $200.64
Income mln
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 1 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for FibroGen Inc is $43.00, about 74.3% above its November 7 closing price of $11.03
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
